neurogenic detrusor overactivity
Urology · 2012–2012
2decisions
2medicines
0carried consumer input
0individual submissions
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| botulinum toxin type A Treatment of urinary incontinence due to neurogenic detrusor overactivity in patients who are not adequately managed by anticholinergic medication. | Jul 2012 | Recommended with restriction | unclear |
| botulinum toxin type a purified neurotoxin complex Treatment of urinary incontinence due to neurogenic detrusor overactivity, as demonstrated by a urodynamic study, in patients who are not adequately managed by… | 2012 | Recommended with restriction | unclear |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.